A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of BPN-14967 in Healthy Adult Subjects
Latest Information Update: 04 Aug 2020
At a glance
- Drugs Tinlarebant (Primary)
- Indications Dry age-related macular degeneration; Stargardt disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Belite Bio
Most Recent Events
- 20 Jul 2020 Results presented in a Belite Bio Media Release.
- 10 Jan 2020 Status changed from recruiting to completed.
- 26 Oct 2019 Planned number of patients changed from 56 to 40.